MetLife Investment Management’s Ocular Therapeutix OCUL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $780K | Sell |
84,066
-9,331
| -10% | -$86.6K | ﹤0.01% | 1447 |
|
|
2025
Q1 | $685K | Buy |
93,397
+663
| +0.7% | +$4.86K | ﹤0.01% | 1548 |
|
|
2024
Q4 | $792K | Buy |
92,734
+2,454
| +3% | +$21K | ﹤0.01% | 1541 |
|
|
2024
Q3 | $785K | Hold |
90,280
| – | – | ﹤0.01% | 1532 |
|
|
2024
Q2 | $618K | Buy |
90,280
+30,947
| +52% | +$212K | ﹤0.01% | 1607 |
|
|
2024
Q1 | $540K | Buy |
59,333
+18,685
| +46% | +$170K | ﹤0.01% | 1633 |
|
|
2023
Q4 | $181K | Hold |
40,648
| – | – | ﹤0.01% | 2292 |
|
|
2023
Q3 | $128K | Hold |
40,648
| – | – | ﹤0.01% | 2461 |
|
|
2023
Q2 | $210K | Hold |
40,648
| – | – | ﹤0.01% | 2246 |
|
|
2023
Q1 | $214K | Buy |
40,648
+13,777
| +51% | +$72.6K | ﹤0.01% | 2177 |
|
|
2022
Q4 | $75.5K | Sell |
26,871
-14,011
| -34% | -$39.4K | ﹤0.01% | 2687 |
|
|
2022
Q3 | $170K | Hold |
40,882
| – | – | ﹤0.01% | 2407 |
|
|
2022
Q2 | $164K | Buy |
40,882
+17,968
| +78% | +$72.2K | ﹤0.01% | 2444 |
|
|
2022
Q1 | $113K | Sell |
22,914
-5,491
| -19% | -$27.2K | ﹤0.01% | 2600 |
|
|
2021
Q4 | $198K | Buy |
28,405
+8,223
| +41% | +$57.3K | ﹤0.01% | 2059 |
|
|
2021
Q3 | $202K | Sell |
20,182
-7,957
| -28% | -$79.6K | ﹤0.01% | 2097 |
|
|
2021
Q2 | $399K | Hold |
28,139
| – | – | ﹤0.01% | 1707 |
|
|
2021
Q1 | $462K | Sell |
28,139
-127
| -0.4% | -$2.08K | ﹤0.01% | 1570 |
|
|
2020
Q4 | $585K | Buy |
28,266
+882
| +3% | +$18.3K | 0.01% | 1408 |
|
|
2020
Q3 | $208K | Buy |
27,384
+6,395
| +30% | +$48.7K | ﹤0.01% | 1844 |
|
|
2020
Q2 | $175K | Hold |
20,989
| – | – | ﹤0.01% | 1980 |
|
|
2020
Q1 | $104K | Buy |
+20,989
| New | +$104K | ﹤0.01% | 2056 |
|
|
2018
Q3 | – | Sell |
-17,358
| Closed | -$117K | – | 2625 |
|
|
2018
Q2 | $117K | Buy |
+17,358
| New | +$117K | ﹤0.01% | 2151 |
|